Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ODI-2001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Capital Grand Est
Deal Size : $2.2 million
Deal Type : Financing
Details : The financing will secure the preparation on Odimma's First-in-Man clinical trial with ODI-2001, an innovative first-in-class personalized immunotherapy against cancer.
Product Name : ODI-2001
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
February 05, 2023
Lead Product(s) : ODI-2001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Capital Grand Est
Deal Size : $2.2 million
Deal Type : Financing
Lead Product(s) : ODI-2001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : ABL Europe
Deal Size : Undisclosed
Deal Type : Agreement
ABL and Odimma Therapeutics Enter Development Agreement
Details : ABL will manufacture the viral component of Odimma's innovative and proprietary immunization platform ODI-2001. The viral component present in ODI-2001 plays the role of both a strong immune adjuvant and of a carrier for the DNA vector expressing persona...
Product Name : ODI-2001
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 17, 2022
Lead Product(s) : ODI-2001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : ABL Europe
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
